Previous Article | Next Article 
Journal of Clinical Microbiology, November 2000, p. 4239-4241, Vol. 38, No. 11
0095-1137/00/$04.00+0
Evaluation of a New Culture Medium for
Borrelia burgdorferi
Adriana R.
Marques,1,*
Frida
Stock,2 and
Vee
Gill2
Laboratory of Clinical Investigation,
National Institute of Allergy and Infectious
Diseases,1 and Clinical Pathology
Department, Warren Grant Magnuson Clinical
Center,2 National Institutes of Health,
Bethesda, Maryland
Received 7 April 2000/Returned for modification 12 July
2000/Accepted 23 August 2000
 |
ABSTRACT |
We evaluated the new MPM medium for the growth of Borrelia
burgdorferi. All 18 blood samples from 17 patients with Lyme
disease were negative. Growth studies showed that by day 4, most
organisms in MPM were not viable. Our results reinforce the use of BSK
medium as the primary choice for growing B. burgdorferi.
 |
TEXT |
Lyme disease is a complex
multisystem infection caused by Borrelia burgdorferi and is
the most common vector-borne disease in the United States
(5). Chronic Lyme disease and posttreatment Lyme syndrome
(CLD/PLDS) are names used to describe the clinical picture of patients
who suffer from chronic symptoms after what is thought to be adequate
antibiotic therapy. The underlying mechanism of these symptoms is
unknown, and the management of these patients is controversial.
Evidence of a persistent infection in these patients, as assessed by
the available direct methods, is generally lacking. Unfortunately,
these methods have low sensitivity in some disease manifestations that
are clearly associated with persistent B. burgdorferi
infection. Therefore, negative results may not exclude the possibility
of persistent infection. For example, B. burgdorferi can be
cultivated in vitro by using an enriched artificial medium, named
Barbour-Stoenner-Kelly medium BSK), supplemented with serum
(2). However, culture of the spirochete from clinical specimens has very low sensitivity outside of samples taken from patients with erythema migrans, where the reported sensitivity varies
from 20 to 90% (7, 9, 13, 14, 16). The yield of this
microorganism in cultures of whole, untreated blood from patients with
acute disease has usually been 5% or less (6), but the use
of plasma, serum, and larger quantities of blood has increased the
yield to about 25% to 50% in blood samples from patients with early
disease who have not received antibiotics (17, 18). Culture
of cerebrospinal fluid yields bacteria in less than 10% of samples
(8), and the spirochete has never been reliably cultured
from joint fluid. PCR results have been variable and usually are
similar to the culture results (6, 11, 13-15). The
exception is for joint fluid from patients with Lyme arthritis, where
PCR sensitivity is up to 85% (10).
In 1998, Phillips et al. described a new medium and methods for
culturing B. burgdorferi, called MPM. Using this new medium, they reported being able to culture B. burgdorferi from the
blood of 43 of 47 patients with CLD/PLDS, all of whom had relapsed
after long-term oral and intravenous antibiotics (12). Such
an improvement in culture sensitivity would be a major advance in the
laboratory diagnosis of Lyme disease. In a prospective evaluation of
MPM and BSK for blood cultures from CLD/PLDS patients, we were unable to duplicate the findings of Phillips et al. We tested 18 blood samples
from 17 patients evaluated at the National Institutes of Health (NIH)
Clinical Center between July and September 1999. The patients included
10 patients referred to the NIH with suspected CLD/PLDS, 5 patients
with Lyme arthritis, 1 patient who had recovered from Lyme disease, and
1 patient with early Lyme disease. The patients were from Maryland
(n = 12), New Jersey (n = 2),
Massachusetts (n = 1), Wisconsin (n = 1), and Florida (n = 1). The patients with
suspected CLD/PLDS had a history of Lyme disease according to the
Centers for Disease Control and Prevention (CDC) clinical definition
(six had a history of erythema migrans), positive serologic analysis
confirmed by immunoglobulin G Western blot analysis using the CDC
interpretation criteria (3, 4), and persistent or intermittent symptoms for at least 6 months after appropriate antibiotic therapy. The usual symptoms included widespread
musculoskeletal pain and fatigue, memory and/or concentration
impairment, radicular pain, and paresthesias or dysesthesias. The onset
of symptoms was coincident with or within 6 months of initial B. burgdorferi infection, the symptoms were significant enough to
interfere with daily activities, and other causes were excluded. PCR of
cerebrospinal fluid and blood, using the outer surface protein A gene
target or the 16S RNA gene target, was negative in all CLD/PLDS
patients. Patients with Lyme arthritis had mono- or oligoarticular
arthritis, primarily of large joints, exposure to a known area of
endemic infection, exclusion of other causes, and positive Lyme disease serologic test results. The patient who recovered from Lyme disease was
asymptomatic 1 year after receiving therapy for early neuroborreliosis (disseminated erythema migrans, lymphocytic meningitis, and bilateral facial nerve palsy). The patient with early Lyme disease had localized erythema migrans and fever. Two 5-ml blood samples were collected in
EDTA tubes from each patient. From these, one MPM culture and one BSK
culture (described below) were processed from each of 17 participants,
while 1 participant had 2 sets of cultures done. The study was approved
by the National Institute of Allergy and Infectious Diseases
Institutional Review Board, and all patients signed informed-consent forms.
The MPM medium was prepared as described by Phillips et al., except
that NIH (Bethesda, Md.) distilled water rather than Detroit tap water
was used. Briefly, the MPM formula contained the following per liter of
water: 20 g of proteose peptone, infusion from 1,000 g of beef,
10 g of dextrose, 10 g of NaCl, 4 g of dipotassium phosphate, 1 g of sodium thioglycolate, 1 g of purified agar, 0.004 g of Bacto Methylene Blue, 100 g of sucrose, and 5 g of soluble starch. The medium was autoclaved for 15 min at 120°C and
refrigerated overnight before the final tube and slide cultures were
prepared. To prepare the tube cultures, 10 ml of medium was boiled to
melt the agar, and 1 ml of a sterile 10% solution of autoclaved yeast
extract and 1 ml of a sterile solution of NaHCO3 were
added. The slide cultures were prepared similarly, except that 3 ml of
the yeast extract solution and 10 ml of the NaHCO3 solution
were added to 30 ml of the basal medium and the mixture was then poured
into a sterile Coplin jar. To make the blood agar plates, the agar
content was adjusted to 16 g/liter and 60 ml of sheep blood was added
directly after autoclaving the medium to prepare a chocolatized agar.
Sterile yeast extract was also added to a final concentration of 1%.
Tube, slide, and plate cultures were performed using blood (0.1 ml/tube, 0.1 ml/slide, and 0.5 ml/plate) as specified in the procedures
of Phillips et al. (12). The cultures were incubated at
30°C and held for 4 weeks. Samples were taken from the tube cultures
at 2, 4, 7, 14, and 21 days for staining with acridine orange (AO). AO
stain (Becton Dickinson Microbiology Systems, Sparks, Md.) contains
0.1 g of acridine orange in 1 liter of 0.5 M acetate buffer (pH
4.0). The slides were fixed in methanol for 2 min, stained with AO for
2 min, and read with a 40× objective. All 18 cultures were negative by
tube, slide, and plate cultures.
Simultaneously, blood cultures in BSK broth were prepared by our
standard Borrelia culture method. Approximately 2 to 4 ml of
plasma from each patient was inoculated into 100 ml of BSK broth
containing rabbit serum (Sigma, St. Louis, Mo.). These cultures were
incubated at 35°C, examined visually for growth once a week, and
stained with AO if growth appeared to be occurring or at the end of the
4-week incubation period. All 18 BSK blood cultures were negative.
To further document the comparative growth characteristics of MPM and
BSK, we used B. burgdorferi strain HB19 to perform a series
of growth studies. High-passage B. burgdorferi sensu stricto HB19 was obtained from the Rocky Mountain Laboratories. HB19 was originally isolated from the blood of a patient from Connecticut (1). Table 1 describes the
results of cultivation of a series of 10-fold dilutions of a suspension
(106 organisms/ml) of the organism. A 1-ml volume of each
dilution was inoculated into tubes of MPM broth and of BSK broth. After incubation, each broth culture was examined for growth by AO staining, which is more sensitive than the Gram stain for the detection of
slender organisms. AO stains bacteria by binding to bacterial DNA, and
when the staining is done at low pH, it results in bright orange
fluorescence of viable bacteria while background debris are generally
yellow to green. Estimates of growth were determined by determining the
number of organisms per high-power field if organisms were numerous or
per slide if organisms were very few. Although staining the organism
could be demonstrated equivalently in both media on day 2 by AO
staining, the majority of organisms in MPM were green rather than
orange by day 4, suggesting decreasing viability. Growth was readily
apparent in all except the highest dilution of the BSK, reaching an
optimum at around 7 days. However, no significant growth occurred at
any dilution of the MPM series. Subcultures from each of the BSK and
MPM tubes into new tubes of BSK at 3 weeks confirmed that the organisms
from the BSK tubes were still viable while those from the MPM tubes
were nonviable and did not initiate growth when transferred to fresh
medium (either MPM or BSK).
This study demonstrates that the use of MPM does not enhance the
detection of B. burgdorferi from cultures of blood samples from CLD/PLDS patients. We were unable to recover the spirochete from
the blood of patients with CLD/PLDS by using either this new medium or
BSK. Using a reference strain of B. burgdorferi, we have
also presented evidence that culturing in BSK remains the best method
for growing and maintaining B. burgdorferi in medium.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Bldg. 10, Room
11N228, NIH, 10 Center Dr., Bethesda, MD 20892-1888.
 |
REFERENCES |
| 1.
|
Barbour, A. G.,
S. L. Tessier, and W. J. Todd.
1983.
Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody.
Infect. Immun.
41:795-804[Abstract/Free Full Text].
|
| 2.
|
Barbour, A. G.
1984.
Isolation and cultivation of Lyme disease spirochetes.
Yale J. Biol. Med.
57:521-525[Medline].
|
| 3.
|
Centers for Disease Control and Prevention.
1995.
Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.
Morb. Mortal. Wkly. Rep.
44:590-591[Medline].
|
| 4.
|
Centers for Disease Control and Prevention.
1997.
Case definitions for infectious conditions under public health surveillance.
Morb. Mortal. Wkly. Rep.
46:1-55[Medline].
|
| 5.
|
Centers for Disease Control and Prevention.
1997.
Lyme disease United States, 1996.
Morb. Mortal. Wkly. Rep.
46:531-535[Medline].
|
| 6.
|
Goodman, J. L.,
J. F. Bradley,
A. E. Ross,
P. Goellner,
A. Lagus,
B. Vitale,
B. W. Berger,
S. Luger, and R. C. Johnson.
1995.
Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction.
Am. J. Med.
99:6-12[CrossRef][Medline].
|
| 7.
|
Jurca, T.,
E. Ruzic-Sabljic,
S. Lotric-Furlan,
V. Maraspin,
J. Cimperman,
R. N. Picken, and F. Strle.
1998.
Comparison of peripheral and central biopsy sites for the isolation of Borrelia burgdorferi sensu lato from erythema migrans skin lesions.
Clin. Infect. Dis.
27:636-638[Medline].
|
| 8.
|
Karlsson, M.,
K. Hovind-Hougen,
B. Svenungsson, and G. Stiernstedt.
1990.
Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis.
J. Clin. Microbiol.
28:473-479[Abstract/Free Full Text].
|
| 9.
|
Nadelman, R. B.,
J. Nowakowski,
G. Forseter,
S. Bittker,
D. Cooper,
N. Goldberg,
D. McKenna, and G. P. Wormser.
1993.
Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study.
Am. J. Med.
94:583-588[CrossRef][Medline].
|
| 10.
|
Nocton, J. J.,
F. Dressler,
B. J. Rutledge,
P. N. Rys,
D. H. Persing, and A. C. Steere.
1994.
Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis.
N. Engl. J. Med.
330:229-234[Abstract/Free Full Text].
|
| 11.
|
Nocton, J. J.,
B. J. Bloom,
B. J. Rutledge,
D. H. Persing,
E. L. Logigian,
C. H. Schmid, and A. C. Steere.
1996.
Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis.
J. Infect. Dis.
174:623-627[Medline].
|
| 12.
|
Phillips, S. E.,
L. H. Mattman,
D. Hulinska, and H. Moayad.
1998.
A proposal for the reliable culture of Borrelia burgdorferi from patients with chronic Lyme disease, even from those previously aggressively treated.
Infection
26:364-367[Medline].
|
| 13.
|
Picken, M. M.,
R. N. Picken,
D. Han,
Y. Cheng,
E. Ruzic-Sabljic,
J. Cimperman, and F. Strle.
1997.
A two year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis.
Mol. Pathol.
50:186-193[Abstract/Free Full Text].
|
| 14.
|
Schwartz, I.,
G. P. Wormser,
J. J. Schwartz,
D. Cooper,
P. Weissensee,
A. Gazumyan,
E. Zimmermann,
N. S. Goldberg,
S. Bittker,
G. L. Campbell, et al.
1992.
Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions.
J. Clin. Microbiol.
30:3082-3088[Abstract/Free Full Text].
|
| 15.
|
von Stedingk, L. V.,
I. Olsson,
H. S. Hanson,
E. Asbrink, and A. Hovmark.
1995.
Polymerase chain reaction for detection of Borrelia burgdorferi DNA in skin lesions of early and late Lyme borreliosis.
Eur. J. Clin. Microbiol. Infect. Dis.
14:1-5[CrossRef][Medline].
|
| 16.
|
Wormser, G. P.,
G. Forseter,
D. Cooper,
J. Nowakowski,
R. B. Nadelman,
H. Horowitz,
I. Schwartz,
S. L. Bowen,
G. L. Campbell, and N. S. Goldberg.
1992.
Use of a novel technique of cutaneous lavage for diagnosis of Lyme disease associated with erythema migrans.
JAMA
268:1311-1313[Abstract].
|
| 17.
|
Wormser, G. P.,
J. Nowakowski,
R. B. Nadelman,
S. Bittker,
D. Cooper, and C. Pavia.
1998.
Improving the yield of blood cultures for patients with early Lyme disease.
J. Clin. Microbiol.
36:296-298[Abstract/Free Full Text].
|
| 18.
|
Wormser, G. P.,
S. Bittker,
D. Cooper,
J. Nowakowski,
R. B. Nadelman, and C. Pavia.
2000.
Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease.
J. Clin. Microbiol.
38:1648-1650[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, November 2000, p. 4239-4241, Vol. 38, No. 11
0095-1137/00/$04.00+0
This article has been cited by other articles:
-
Feder, H. M. Jr., Johnson, B. J.B., O'Connell, S., Shapiro, E. D., Steere, A. C., Wormser, G. P., the Ad Hoc International Lyme Disease Group,
(2007). A Critical Appraisal of "Chronic Lyme Disease". NEJM
357: 1422-1430
[Full Text]
-
Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., Wormser, G. P.
(2005). Diagnosis of Lyme Borreliosis. Clin. Microbiol. Rev.
18: 484-509
[Abstract]
[Full Text]
-
Bugrysheva, J., Dobrikova, E. Y., Godfrey, H. P., Sartakova, M. L., Cabello, F. C.
(2002). Modulation of Borrelia burgdorferi Stringent Response and Gene Expression during Extracellular Growth with Tick Cells. Infect. Immun.
70: 3061-3067
[Abstract]
[Full Text]
-
Tilton, R. C., Barden, D., Sand, M., Marques, A. R., Stock, F., Gill, V.
(2001). Culture of Borrelia burgdorferi. J. Clin. Microbiol.
39: 2747-2747
[Full Text]
-
McSweegan, E.
(2001). To the Editor. The Journal of School Nursing
17: 170-170
-
McSweegan, E.
(2001). To the Editor. The Journal of School Nursing
17: 170-170